Details
Stereochemistry | ACHIRAL |
Molecular Formula | CO3 |
Molecular Weight | 60.0089 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | -2 |
SHOW SMILES / InChI
SMILES
[O-]C([O-])=O
InChI
InChIKey=BVKZGUZCCUSVTD-UHFFFAOYSA-L
InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4)/p-2
Potash (Dihydroxyaluminum Sodium Carbonate), a component of
Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.drugbank.ca/drugs/DB09460 |
|||
Target ID: CHEMBL205 Sources: https://www.drugbank.ca/drugs/DB09460 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Kompensan Approved UseGastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia |
PubMed
Title | Date | PubMed |
---|---|---|
Exchange of sodium by magnesium in aluminum hydroxycarbonate gel. | 1984 Jul |
|
Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence. | 1990 May-Jun |
|
Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate. | 1991 |
Sample Use Guides
Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
2033-9
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
||
|
DSLD |
747 (Number of products:2)
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
||
|
LOINC |
2034-7
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
||
|
NCI_THESAURUS |
C597
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
||
|
LOINC |
14641-5
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
||
|
LOINC |
2035-4
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000125923
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
CARBONATE
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
D002254
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
7UJQ5OPE7D
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
3812-32-6
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
1544139
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
41609
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
DB14531
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
C82598
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
SUB32966
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
DTXSID70872973
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
19660
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY | |||
|
7UJQ5OPE7D
Created by
admin on Fri Dec 15 16:59:54 GMT 2023 , Edited by admin on Fri Dec 15 16:59:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY